Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
Goldblatt D, Andrews NJ, Sheppard CL, Rose S, Aley PK, Roalfe L, Southern J, Robinson H, Pearce E, Plested E, Johnson M, Litt DJ, Fry NK, Waight P, Snape MD, Miller E. Goldblatt D, et al. Vaccine. 2023 May 5;41(19):3019-3023. doi: 10.1016/j.vaccine.2023.04.017. Epub 2023 Apr 10. Vaccine. 2023. PMID: 37045683 Free article. Clinical Trial.
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Rajan M, Marchevsky N, Sinclair G, O'Brien K, Jefferies K, Owino N, Hallis B, Goldblatt D, Matheson M, Cuthbertson H, Aley P, Liu X, Snape MD. Rajan M, et al. Among authors: goldblatt d. Pediatr Infect Dis J. 2023 Jan 1;42(1):66-73. doi: 10.1097/INF.0000000000003753. Epub 2022 Nov 1. Pediatr Infect Dis J. 2023. PMID: 36476534 Clinical Trial.
Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children.
Kawade A, Dayma G, Apte A, Telang N, Satpute M, Pearce E, Roalfe L, Patil R, Wang Y, Noori N, Gondhali A, Juvekar S, Oron AP, Sanghavi S, Goldblatt D, Dagan R, Bavdekar A. Kawade A, et al. Among authors: goldblatt d. Vaccine. 2023 May 5;41(19):3066-3079. doi: 10.1016/j.vaccine.2023.04.008. Epub 2023 Apr 10. Vaccine. 2023. PMID: 37045679 Clinical Trial.
Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys.
Gallagher KE, Adetifa IMO, Mburu C, Bottomley C, Akech D, Karani A, Pearce E, Wang Y, Kagucia EW, Goldblatt D, Hammitt LL, Scott JAG. Gallagher KE, et al. Among authors: goldblatt d. Lancet Infect Dis. 2023 Nov;23(11):1291-1301. doi: 10.1016/S1473-3099(23)00206-2. Epub 2023 Jul 7. Lancet Infect Dis. 2023. PMID: 37429307 Free article.
Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.
Kalizang'oma A, Swarthout TD, Mwalukomo TS, Kamng'ona A, Brown C, Msefula J, Demetriou H, Chan JM, Roalfe L, Obolski U, Lourenço J, Goldblatt D, Chaguza C, French N, Heyderman RS. Kalizang'oma A, et al. Among authors: goldblatt d. J Infect Dis. 2024 Mar 26:jiae040. doi: 10.1093/infdis/jiae040. Online ahead of print. J Infect Dis. 2024. PMID: 38530917
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
Gálvez NMS, Pacheco GA, Schultz BM, Melo-González F, Soto JA, Duarte LF, González LA, Rivera-Pérez D, Ríos M, Berrios RV, Vázquez Y, Moreno-Tapia D, Vallejos OP, Andrade CA, Hoppe-Elsholz G, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVacCL03 Study Group; González-Aramundiz JV, Johnson M, Goldblatt D, González PA, Abarca K, Bueno SM, Kalergis AM. Gálvez NMS, et al. Among authors: goldblatt d. Elife. 2022 Oct 13;11:e81477. doi: 10.7554/eLife.81477. Elife. 2022. PMID: 36226829 Free PMC article. Clinical Trial.
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I, Futa A, Saidy-Jah E, Edem B, Akpalu E, Dibbasey T, Sethna V, Dhere R, Kampmann B, Bengt C, Sirr J, Hosken N, Goldblatt D, Antony K, Alderson MR, Lamola S, Clarke E. Adigweme I, et al. Among authors: goldblatt d. Lancet Infect Dis. 2023 May;23(5):609-620. doi: 10.1016/S1473-3099(22)00734-4. Epub 2023 Jan 10. Lancet Infect Dis. 2023. PMID: 36638819 Clinical Trial.
Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing.
Wijaya R, Johnson M, Campbell N, Stuart B, Kelly A, Tipler N, Menne T, Ahearne MJ, Willimott V, Al-Naeeb AB, Fox CP, Collins GP, O'Callaghan A, Davies AJ, Goldblatt D, Lim SH; PROSECO investigators. Wijaya R, et al. Among authors: goldblatt d. Lancet. 2023 Jul 8;402(10396):99-102. doi: 10.1016/S0140-6736(23)01180-7. Epub 2023 Jun 29. Lancet. 2023. PMID: 37393922 Free article. No abstract available.
Socioeconomic and Demographic Risk Factors for SARS-CoV-2 Seropositivity Among Healthcare Workers in a UK Hospital: A Prospective Cohort Study.
Lam T, Saso A, Torres Ortiz A, Hatcher J, Woodman M, Chandran S, Thistlethwayte R, Best T, Johnson M, Wagstaffe H, Mai A, Buckland M, Gilmour K, Goldblatt D, Grandjean L; COVID-19 Staff Testing of Antibody Responses (Co-STARs) Study Team. Lam T, et al. Among authors: goldblatt d. Clin Infect Dis. 2024 Mar 20;78(3):594-602. doi: 10.1093/cid/ciad522. Clin Infect Dis. 2024. PMID: 37647517 Free PMC article.
437 results